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ABSTRACT
Exosomes are biologically active nanovesicles from endosomal origin and lipid bilayer
involved in cell communication, secreted by dierent types of cells and present in a wide
variety of biological fluids. Due to their size, liposome-like characteristics and their strong
relation with oncology, new applications for therapy and diagnosis are being explored in
the field of medical imaging.
During this thesis, the isolation, characterization and functionalization with fluores-
cent dyes has been performed to examine the possibility of using goat’s milk derived
exosomes as theragnostic platform. With this purpose, the size, shape and charge of ex-
osomes have been characterized, and the conjugation with two dierent fluorophores has
proved to unalter their physicochemical properties. The biodistribution of functionalized
exosomes, their toxicity and in vitro accumulation have been analyzed to evaluate that
these nanovesicles can be used not only for diagnosis, but also for therapy and drug de-
livery in the future.
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1. MOTIVATION AND OBJECTIVES
1.1. Motivation
Cancer is a generic term grouping a collection of dierent diseases with the common fea-
ture of the rapid growth of abnormal cells, which do not stop dividing and can spread to
other organs or parts of the body [1]; it is an extremely complex disease for which many
of their mechanisms of action remain unclear despite have been extensively studied over
the years.
Roughly, one of every six deaths worldwide are caused by any type of cancer, being it
the second leading cause of death. The number of deaths in the world in 2016 is estimated
between 8.75 and 9.1 million by the Institute of Health Metrics and Evaluation (IHME)
[2]; converting cancer in one of the diseases with higher incidence and human-life costs
over the world population. For many types of cancer, the strongest chance of survivabil-
ity and/or increased quality of patient’s life during the treatment still resides in an early
detection, before the tumour spreads to adjacent tissues or to distant organs through the
blood or lymphatic system [3].
Dierent platforms have been developed for both early diagnosis and treatment of
tumours, being many of them based on synthetic liposomes, which present serious dis-
advantages due to their chemical origin. The proposed work for this thesis is the use of
natural liposome-like nanoparticles that would allow the non-invasive localization of both
primary and metastatic tumours with a single screening, which would imply a time and
cost-eective technique for early detection of cancer. Additionally, with further research
it would be possible to use the aforementioned nanoparticles as drug carriers that will
attach only the desired aberrant cells and their microenvironment without aecting the
healthy tissue. For the present study, exosomes derived from goat milk have been used to
determine their potential applications as a theragnostic tool applied in oncology.
1.2. Objectives
The main purpose of this Bachelor Thesis is the evaluation of caprine milk-derived exo-
somes as a new theragnostic platform in oncology.
To do so, several minor objectives have been stated, being (i) the optimization of ex-
traction methods and purification methods by introducing changes to the most commonly
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used techniques, (ii) the characterization of the resulting exosomes to ensure that the pop-
ulation of extracellular vesicles accurately corresponds to exosomes, (iii) the validation
of the fluorescent labelling of exosomes for their use as molecular probes for cancer co-
localization and (iv) the analysis of the eects of the exosomes both in vivo and in vitro
(focusing mainly on toxicity, biodistribution and accumulation in tumours).
2
2. INTRODUCTION
2.1. Biological background
Exosomes are biological lipid bilayer-enclosed extracellular vesicles of endosomal origin,
secreted by dierent tissues and cells under physiological and pathological conditions,
being present in an extensive variety of body fluids (including serum, breast milk, saliva,
tears, amniotic fluid or urine) [4] [5]. They are originated through the endocytic pathway
by the fusion of multivesicular bodies with the plasma membrane [6], with functions re-
lated to the regulation of pathophysiological processes and cell communication, including
immune responses, inflammation, tumour growth, infection and the modulation of con-
crete cellular activities [7] [4].
Fig. 1. Schematic representation of exosomes and microvesicles formation. Endocytic pathway
involves the inward budding of endosomes into multivesicular bodies, which fuse with the
membrane to release the exosomes [8].
It is important to dierentiate between exosomes and microvesicles, since both are
extracellular vesicles released by healthy cells to the extracellular space, with functions
related with cell-cell signalling. Despite those similarities, exosomes and microvesicles
are dierent populations within the extracellular vesicles with dierentiated properties,
sizes and characteristics as their lipid and protein composition, the shape of the mem-
brane, the diusion coecient or their cargo content [9]. Thus, they are believed to have
distinct roles in the regulation of a broad range of biological processes [10].
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Exosomes are involved in intercellular communication and cell-cell signalling via
their functionally active cargo, which contains miRNA, mRNA, DNA, lipids, metabo-
lites and proteins related to transport, immunological responses and tumour progression
[11]. Delving into the tumour-related functions of exosomes, these vesicles have shown
determining relevance in oncology due to their active role in tumorigenesis, cancer pro-
gression, immune evasion and angiogenesis, since they have proved to be able of alter-
ing tumour microenvironments and to be related with the establishment of premetastatic
niches and the remodelling of extracellular matrices [12] [13].
Fig. 2. Graphic representation of structure and content of exosomes[14].
Exosomes allow the exchange of information not only between neighbouring cancer
cells but to communicate with dierent cell types at distant sites [15]. Recent studies have
demonstrated that exosomes derived from cancer cell lines are able to promote metastasis
of primary tumours [16], thus allowing the conditioning of the issue to allow coloniza-
tion. Due to these properties related with tumour migration and pre-metastatic niches,
the role of non-tumour derived exosomes is starting to be considered as well as their pos-
sible use as a non-toxic and biocompatible nanosized platform for drug delivery [12] [15].
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2.2. Molecular imaging
Molecular imaging is a set of techniques that allow to visualize, characterize and measure
biological processes at cellular level, favouring the study of pathways and disease mech-
anisms [17]. During last years, the impact of molecular imaging on the diagnosis and
therapy of cancer has increased due to the possibility of combine morphologic, functional
and metabolic techniques in an in vivo multimodal image [18]. Other advantages lever-
aged by this set of techniques are their capability of imaging alterations taking place at the
molecular level, rather than the final eects of these changes and the high sensitivity and
specificity of the techniques [19] [20]. Concretely applied to cancer, molecular imaging
provides tumour location in the body as well as the visualization of the expression and
activity of related molecules and biological processes that aect the tumoral behaviour
[21].
Imaging applied to oncology is currently an integral part of diagnosis and therapy pro-
tocols, due to its capability of providing structural, metabolic and functional information,
contributing enormously to the clinical decision-making, for example in the guidance of
cancer treatments [22]. Additionally, it allows accessibility to the tumour without tissue
damage, minimum invasion and real-time monitoring, which makes the techniques an im-
portant tool for early diagnosis [23].
2.2.1. Optical imaging
Optical imaging has emerged as an equally functional and non-invasive technique that
enables real-time and high spatial resolution, presenting some advantages over the afore-
mentioned techniques as their reduced side eects (since optical probes do not require
ionizing radiation in comparison with the gold standard technique, nuclear imaging), fi-
nancial costs (price of optical fluorescence cameras and probes is lower than those re-
quired for nuclear imaging) and their potential application in the identification of aicted
areas during interventions in guide surgery [26].
This technique takes advantages of visible light and the properties of photons to ob-
tain insights into not only organs or tissues, but also cells and molecules; it is particularly
useful for the visualization of soft tissues due to the varied absorption and scattering of
light from dierent tissues. Additionally, the visualization of several properties or objects
of interest can be done simultaneously due to the dierent spectrums provided by the
available optical probes [27].
An important consideration of medical imaging probes is the requirement of an appro-
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priate intensity of signal, suciently bright to be detected over the background noise and
dierentiable enough between structures of dierent tissues. In the development of new
probes for biomedical applications, the use of liposomes (artificial phospholipid bilayer
microvesicles) has experimented an increase in the last years due to their characteristics,
among them standing the possibility of incorporating hydrophilic and hydrophobic fluo-
rophores to their membrane structure [28]. As exosomes oer important advantages over
liposomes [8], as it will be detailed in section 2.2.2, the use of labelled exosomes in optical
imaging results of extreme interest.
2.2.2. Fluorescent probes
Fluorescence microscopy is an imaging technique based on the excitation of a fluo-
rophore, that is, a molecule that can re-emit light upon light absorption, which, when
illuminated with high energy light, emit light of a lower frequency allowing its detection
on the microscope. This technique is of high importance since it can be used to detect and
distinguish specific molecular components (called probes) inside the cells, which results
of vital importance in the study of a broad amount of cellular processes [29].
Fluorescently conjugated probes are widely used to enable the visualization of events
in cell death and assess cell viability. For the experimental procedures carried out in this
thesis, two fluorophores were used: Cyanine and Sulfo-Cyanine 7.5 NHS Ester, which
are near-infrared dyes used for the fluorescent labelling of exosomes with the intention to
avoid the range of the light spectrum in which cellular components show autofluorescence
[30].
Cyanine dyes are molecules containing polymethine bridges between two nitrogen
atoms with a delocalized charge; NHS esters are the amine-reactive derivative of the
aforementioned compounds. The dierences between the two mentioned cyanine dyes
reside in the presence of sulfo groups in the case of Sulfo-Cyanine, rendering the dye
hydrosoluble instead of requiring organic co-solvent as Dimethyl Sulfoxide (DMSO) and
aecting the molecular weight of the probe. Additionally, sulfonated cyanines are less
prone to aggregation due to the charged sulfonate groups. The dierences in the spectral
properties are minimum, having both maximum excitation at 750 nm and emission and
773 nm [31].
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Fig. 3. Absorption and emission spectra of Sulfo-Cyanine 7.5 NHS ester (left). Molecular
structures of Cyanine (top right) and Sulfo-Cyanine (bottom right) [31].
2.3. Technological relevance
Cancer is one of the deadliest groups of illnesses worldwide, and increasing the eective-
ness of treatments with early detection, together with the finding of non-invasive biomark-
ers for abnormal tumour cells result of enormous importance. Additionally, this detection
methods suppose a significative contribution to currently used techniques as fine needle
aspiration, which obtain samples “blindly” from tissues, relying to locate and access the
tumour at first attempt. Using exosomes as markers for localization, tumours can be non-
invasively situated, improving sample collection and treatment localization, preventing in
this way unnecessary manipulation of healthy surrounding tissues [32].
Advances in the development of specific imaging techniques carried out during the
last years have found obstacles regarding the clinical applications, mainly limited by tox-
icity of the probes, host immune responses or diculties in their large-scale production
in a cost-eective way. The use of exosomes as platform for medical imaging in oncol-
ogy would overcome most of these drawbacks. Due to their lipidic layer and liposome-
like structure and behaviour, thoroughly described in literature [28] [33] [34], exosome
exploitation as drug carrier oers all the advantages considered for liposomes, without
the drawbacks of these synthetic nanoparticles. Thus, these naturally derived nanoparti-
cles have a strong potential as chemotherapeutic agent and drug delivery vehicle, being
a possible solution for the limitations of synthetic nanoparticles. This is due to several
advantages that include the following:
 Their tolerance and non-toxicity within the own body and when injected in foreign
species. Concretely, investigations have showed that bovine milk exosomes are
cross-species tolerant, causing no immunological or inflammatory eects [15] [35].
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 The presence of an active cargo within the exosome that can be altered to use exo-
somes as drug carriers [15].
 Their ability to be internalized by cells [36].
 The possibility of attachment of ligands to increase the targetability and direct the
drug delivery [8].
Despite the advantages exhibited by exosomes over other synthetic liposome-like
nanoparticles and over other natural particles used for the same purpose - as mesenchymal
cells [37] [38] -, dierent sources of exosomes are currently known. Between those, milk
exosomes were used instead of human-derived ones for two main reasons: there is a need
for safe, scalable and profitable method of production of exosomes, and the security that
no adverse eects are caused [15].
 On the contrary to human exosomes, goat’s milk is readily available and easy to
obtain, allowing an easy to overcome step through their high production and com-
mercialization; also, they don’t entail biocompatibility problems as caprine and
bovine milk have been ingested by human beings for millenniums, ensuring at first
glance that no toxic eects are caused.
 The main advantage of milk-derived exosomes compared to other types of exo-
somes, as tumoral ones, is their absence in participation of pre-oncologic processes,
as it was demonstrated that oncogenic cells produce miRNA that induces tumorige-
nesis and thus, further tumour progression and metastasis [39].
With respect to the use of milk resulting from goats instead of cows, it is due to the
lower amount of fat present in caprine milk, which leads to a reduced number of purifi-
cation steps, which necessarily increases the preservation of the exosome. This causes
the extraction process to be easier and less time-consuming (which is one of the main
drawbacks of the isolation technique) [40] [41].
Additional advantages of using exosomes over any other type of synthetic nanoparti-
cles is the possibility of conjugation with other biological molecules or dyes without the
alteration of their membrane or properties due to the presence of lipids and biomolecules
in the surface. This allows the functionalization with fluorescent probes, which permit
non-invasive tracking in vivo using molecular imaging.
The last important factor that must be taking into account when considering the use of
exosomes as a new theragnostic platform for oncology is that, as liposome-like synthetic
particles, exosomes take advantage of the Enhanced Permeability and Retention Eect
(EPR), which enhances their accumulation in tumours. Thanks to this eect, nanopar-
ticles and other small particles have a tendency to accumulate in tumour tissues due to
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the angiogenesis produced by Vascular Endothelial Growth Factors (VEGF). These new
vessels that nurture solid tumours are characteristically leaky, with reduced lymphatic
drainage; this causes the nanoparticles (which are generally stable in circulation when
they are suciently small to avoid the detection by the reticuloendothelial system but at
the same time not small enough to be excreted through the kidney) to leak through the
permeable tumour vasculature and to be retained there due to the poor lymphatic drainage
[42].
2.4. State of the art
Exosomes have been a hot topic during the last years due to their role in numerous pro-
cesses; particularly related to oncology, they have been widely used as tumour biomark-
ers. Moreover, their size in the range of nanometres, natural origin and liposome-like
structure suggest their use as nanocarriers for both diagnostic and therapeutic applica-
tions [8].
Because of this, multiple studies have been performed with exosomes. Most of them
focus on their role in the modulation of the immunological response [4] [5], studying
human-derived vesicles; others try to determine their internalization method, their se-
cretion pathway or their cargo content. Some researches focus on the applications of
milk-derived exosomes as drug carriers [6] [15] while further ones attempt to detect the
cancerous exosomes from the human liquids where they are found [43] in a novel tech-
nique known as exosome-based liquid biopsy. Furthermore, it has been demonstrated that
the exosomal cargo varies between healthy and tumour cells [35], allowing the detection
of the presence of a tumour by analysing the cargo content of the exosomes [43]. This
dierential expression is linked to unbalanced homeostasis and constitutes a reflection of
the metabolic state of the cells of origin by presenting concrete specific surface proteins
and the parental RNA and protein profiles [39]. These investigations confirm that exoso-
mal nucleic acids can be utilized to find genetic signatures in patients with cancer.
As it can be seen, most of the research currently performed focus in the alteration or
identification of the cargo for drug delivery or specific cancer detection. However, the
intended approach of this work diers in the diagnosis method: instead of collecting sam-
ples related with the suspected origin of the tumour (liquid biopsy) and using the exosome
cargo (either miRNA, proteins or other content) as biomarkers, labelled exosomes would
be used as molecular markers and, by molecular imaging techniques, the tumour would
be detected with independence of its origin. With this spatial information, further anal-
ysis could be performed, as the collection of the body fluid or the fine aspiration needle
technique for confirmation of the type of tumour.
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Although the study of the use of exosomes has suered a dramatic increase during last
years, little work has been found related with the use of the exosome itself as a molecular
probe in the biomedical imaging field [15] [44].
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3. MATERIALS AND METHODS
For the evaluation of goat’s milk derived exosomes as theragnostic paltform in on-
cology, the experiments were focused in several areas: first, in the development of an
optimized protocol for the extraction of pure exosomes and their characterization; then,
in the improvement of a conjugation method to allow the detection and tracking of exo-
somes with optical imaging, and finally, in the evaluation of the eects of exosomes in
vitro. To do so, their toxicity and uptake were assessed in dierent types of cells. Ad-
ditionally, the conjugation technique was evaluated to test its robustness not only with
milk exosomes but with exosomes derived from cancer cells; for this validation, cancer
exosomes were isolated, characterized and conjugated.
The dierent sections detail the techniques used for the extraction and purification
of the exosomes to obtain the most genuine extract possible, their characterization to
claim that the expected nanovesicles are obtained, their conjugation to allow their use in
molecular imaging, and the studies of uptake and toxicity in tumours and organs.
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Fig. 4. Flowchart of the dierent experiments carried out to complete the stablished objectives.
3.1. Milk collection
One litre of commercial skimmed pasteurised goat’s milk ’Cantero de Letur’ was acquired
at the market and stored at 4oC for exosome isolation within the next days.
One litre of fresh whole unpasteurised goat’s milk (unknown week of lactation) col-
lected from a dairy herd located on the outskirts of Madrid. Milk was kept refrigerated
until its arrival and then, aliquoted (40 ml) and stored at -20oC until its use.
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3.2. Isolation and purification of milk exosomes
Isolation of exosomes derived from goat’s milk by means of dierential centrifugation
and ultracentrifugation was performed based on protocols from Munagala, Radha et al.
[15] and Vaswani, Kanchan et al. [45] combined with curdling agent used for further pro-
tein precipitation and increased number of low speed and ultracentrifugations (>50,000
x g) [46]; an additional purification step with PD-10 desalting columns was introduced,
resulting in the optimized protocol presented in Fig. 5.
Protocol#
Number of
low speed
centrifugations
Number of
ultra-
centrifugations
Curdling agent Filtration
Munagala
et al
1 2
No, but cheese
colth used
0.22 m
Vaswani et al 2 2 No qEV column
Optimized
protocol
4 5 Yes PD-10 columns
Table 1. Comparison of dierent methods for isolation of milk exosomes
Briefly, milk aliquots (30 ml) were centrifuged at 5,000  g in 50 ml polycarbonate
tubes with cap (Beckman Coulter, Brea, California) using a JA 30.50 Ti fixed 34o angle
rotor and Avanti J-301 centrifuge (Beckman Coulter) at 4oC for 10 minutes to eliminate
fat globules and the main layer of fat. The supernatant is collected and a 0.5% with re-
spect to the original volume of the sample of curdling agent is added; the polycarbonate
tubes containing the mixture are incubated during 20 minutes in a static system (a water
bath is used) and then centrifuged at 5,000 x g for 10 minutes at 4oC with the aforemen-
tioned centrifuge in order to remove rests of fat and curdling agent. The supernatant is
collected and centrifuged at 13,000  g, 4oC for 30 minutes to separate exosomes from
microvesicles. This procedure is then repeated at 35,000  g for 35 minutes to precipitate
casein and cell debris and at 100,000  g at 4oC for 60 min to precipitate exosomes. This
supernatant is discarded and the exosome pellet obtained is washed and resuspended with
PBS (Sigma-Aldrich, St. Louis, MO) to give homogeneous suspension. The resuspended
exosomes in PBS are centrifuged at 100,000  g at 4oC for 90 minutes, the supernatant
discarded and the pellet of exosomes resuspended in PBS; this procedure is repeated three
times to ensure the precipitation of exosomes. After the third ultracentrifugation, the pel-
let of exosomes is resuspended and pooled in PBS and filtered using a PD-10 desalting
column (Sigma-Aldrich) with bed size of 14.5 mm  50 mm, which allows the pass of
particles of size ranging between 85 and 260 m. Eluted fractions 2 and 3 are collected
while the rest (1, 4, 5 and 6) are discarded. The exosomes are then pooled in PBS and
centrifuged at 100,000  g for 90 minutes at 4oC to cause precipitation; the supernatant
is discarded and the pellet is resuspended to give homogeneous suspension. The total
protein content of exosomes is determined and stored in aliquots at -20oC until use.
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Supernatant
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x3
Fig. 5. Flowchart of the optimized protocol developed for the isolation and purification of goat’s
milk derived exosomes.
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3.3. Protein determination
An estimation of protein content of aliquot of isolated exosomes is determined by compar-
ing the protein concentration from the sample with two standard calibration curves made
with known concentrations of albumin from bovine serum (lyophilized powder,  98%,
Sigma-Aldrich). EZBlue gel staining reagent (Sigma-Aldrich) was used to allow the mea-
surement of their respective absorbances at 595 nm and the mathematical calculation of
the concentrations was performed with a MATLAB code of own development.
3.4. Transmission Electron Microscopy
Exosomes were filtered using 0.45 m Millex-HP syringe filter (Merck KGaA, Darm-
stadt, Germany) and diluted 1:100 in PBS; then transported in ice to the National Centre
of Electronic Microscopy in the Complutense University of Madrid. The negative stain-
ing was performed by a technician according to procedure from literature [47]. Briefly,
samples were placed on coated copper grids, then washed with ultrapure water and neg-
atively stained. Transmission electron microscopy (TEM) images were acquired using a
JEOL 1010 TEM (JEOL USA, Inc) by the technician.
3.5. Dynamic Light Scattering
Exosomes were filtered as described previously and transported to the Spanish National
Center of Cardiovascular Research of Madrid. The size distribution and zeta potential of
the isolated exosomes was obtained using a Zetasizer Nano ZS (Malvern Instruments) and
disposable cuvettes DTS0012 (Sigma-Aldrich) according to manufacturer’s instructions.
All samples were evaluated in 3 replicates.
3.6. Flow Cytometry
The Gallios 10 colors, 3 lasers Flow Cytometer (Beckman Coulter) of the Foundation
for the Biomedical Investigation of the Gregorio Marañón Hospital was used for flow
cytometric analysis of blank and fluorescently labelled exosomes. Samples were diluted
1:100 in PBS to avoid saturation and loaded in round-bottom polystyrene tubes for the
analysis with the cytometer [48]. For the data acquisition and analysis (definition of gates
and assay of the fluorescence), Kaluza Acquisition Software was used; for all analyses,
light-scattering detection was performed in log mode. The maximum number of events
and the event rate was not restricted.
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3.7. Conjugation of milk exosomes with fluorophores for molecular
imaging
Goat’s milk derived exosomes were conjugated with Sulfo-Cyanine 7.5 NHS ester and
Cyanine 7.5 NHS ester according to manufacturer’s instructions; the procedure is the
same for both dyes. Briefly, exosomes are brought with PBS to a final volume of 100
l; pH is measured with pH test strips (Sigma-Aldrich) and raised up to 8.5 using 0.1 M
sodium bicarbonate (Sigma-Aldrich). A proportion 1/10 of stock Sulfo-Cyanine 7.5 NHS
ester (scy7.5) dissolved in ultrapure water with a concentration of 16.9 mM is added to
the exosomes. The mixture is kept at 4oC in a shaker at 750 rpm in the dark for 4 hours.
The conjugate is purified using Exosome Spin Columns MW 3000 (Thermofisher Sci-
entific, Holsville, NY) according to manufacturer’s indications: column is hydrated with
PBS and allowed to achieve gelation, then the excess of PBS is removed by centrifugation
and the sample is charged; the excess of dye is cleared away with further centrifugation.
3.8. In vivo biodistribution in healthy animal
Two healthy mice (n = 1 per group) were used to analyse the biodistribution of exosomes
administered via intravenous injection of exosomes conjugated with fluorophore and the
NIR fluorescent dye itself. The procedure was carried out by the Molecular Probes group
of the Foundation for the Biomedical Investigation of the Gregorio Marañón Hospital
without my contribution, although the results obtained were significant for my posterior
studies.
3.9. Cell culture
Mouse melanoma (B16F10), human adenocarcinoma (HeLa) and glioblastoma (U87) and
mouse primary hepatocytes were ceded by the Cell Culture Unit of the Gregorio Marañón
Hospital. All cell lines were supplemented with 10% heat-inactivated foetal bovine serum
(Gibco, Life Technologies USA) and 1% glutamine (Thermofisher Scientific). FBS had
previously been centrifuged at 100,000  g for 3 hours and filtered with a 0.22 m fil-
ter to remove bovine exosomes that could interfere with the studies. The B16F10 cells
were grown in RMPI, the HeLa, U87 and hepatocytes were in DMEM (Lonza/Clonetics
Corporation, San Diego, CA). All cell lines were cultivated at 37oC and 5% CO2 in a
humidified chamber.
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Primary hepatocytes were isolated by the hepatogastric lab of the Foundation for the
Biomedical Investigation of the Gregorio Marañón Hospital, headed by Dr. Javier Va-
quero. Cells were obtained by smashing and filtering the liver of euthanized mice to
disregard the tissue. Dierential centrifugation using Percoll solution (Sigma-Aldrich)
was performed to obtain isolated hepatocytes, which were sow in attachment media in
culture plaques with their bottom previously covered with a 1:1000 solution of collagen
type I (Sigma-Aldrich). Attachment media is made with DMEM, F12 (Thermofisher Sci-
entific), glutamine, HEPES (Thermofisher Scientific), glucose, inactive FBS, BSA and
antibiotic. Media was changed every day or before the addition of exosomes -depending
on the requirements of the experiment- using regular DMEM without exosomes.
3.10. Isolation of exosomes derivative from cancer cells
The isolation was performed using a simplified dierential centrifugation protocol with
no purification steps described in literature [52].
The cellular medium where the dierent cancer cells (B16F10, HeLa, U87) were cul-
tured was aliquoted and stored at -20oC until the extraction of exosomes. The same cen-
trifuge and tubes than the described in section 3.2 from methodology were used. Briefly,
60 ml of each type of cell medium was centrifuged at 300 x g for 10 minutes to eliminate
cells. The supernatant was then collected a centrifuged at 2,000 x g for 10 minutes to
eliminate dead cells, subsequently at 10,000 x g for 30 minutes to get rid of cell debris
and finally at 100,000 x g for 70 minutes to precipitate the exosomes. The supernatant
was discarded and the pellet of exosomes was washed and resuspended in PBS, then cen-
trifuged at 100,000 x g for 70 minutes and resuspended in PBS to increase the purity of
the isolated exosomes.
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supernatant
supernatant
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contaminating proteins
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Fig. 6. Flowchart summarizing the process of isolation of exosomes derived from tumoral cells
from Thery et al. [52]
3.11. Characterization and conjugation of cancer cells exosomes
Exosomes derived from cancer cells were conjugated applying the same protocol used for
the functionalization of milk exosomes (section 3.7) and characterized using the afore-
mentioned techniques employed for the characterization of goat’s milk derived exosomes
(protein determination (3.3), TEM (3.4), DLS (3.5) and flow cytometry (3.6)).
3.12. In vitro toxicity assessment
Potential short-term toxicity of exosomes was tested in vitro for all previously mentioned
cell lines using MTT assay. Cells were first cultured for 24 hours in 96-well plates. To
improve the attachment of cells to the bottom of the culture plaques (Costar, Sigma-
Aldrich), they were covered with dissolution 1:1000 of collagen type I (Sigma-Aldrich)
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up to a 5% of the maximum volume of the well; then sterilized in ultraviolet light for an
hour at room temperature before seeding. Tumor cells previously grown in flasks (Sigma-
Aldrich) with less than three passages were lifted and quantified in a Neu Bauer chamber
(Sigma-Aldrich) according to the product instructions. Hepatocytes were obtained as de-
scribed in section 3.9; the counting was performed following the same procedure as for
tumor cells. Roughly 5,000 cells, either cancer or liver cells, were seeded in 200 l of
their corresponding cell culture media per well, and incubated overnight at 37oC.
Doses of dierent concentrations, usually of subsequent orders of magnitude (50, 5,
0.5, 0.05 g/ml) were added and incubated for either 24 or 48 hours before the MTT assay.
To assess the toxicity, 1/10 of Thiazolyl Blue Tetrazolium Bromide (powder, 98%, Sigma-
Aldrich) with concentration 5 mg/ml is added per well and incubated over 3 hours at
37oC. After that period, the whole content of the wells is removed and 100 l of Dimethyl
Sulfoxide (Sigma-Aldrich) is added per well to dissolve the formazan crystals formed.
Incubation at room temperature in shaker for half an hour is performed to improve the
dissolution of these crystals. Then, absorbance is measured at 595 nm.
3.13. In vitro uptake studies
The uptake of exosomes by cancer cells (B16F10, HeLa and U87) was assessed with con-
focal microscopy as described in next section. For sample preparations, culture plaques
were prepared by introducing one cover slip glass per well and covering 1/7 of the well
volume with dissolution 1:1000 of collagen type I solution, then sterilized in ultravio-
let light for an hour at room temperature. Collagen removed before seeding of 20,000
tumour-derived cells from previously grown flasks with less than three passages in 500
l of their corresponding cell culture media per well. Cells were incubated overnight at
37oC before the former study.
Dierent doses of sulfo-cyanine conjugated exosomes (5 and 0.5 g/ml) were added
at separated times (30 min, 1, 2, 4 and 24 hours) in order to allow the fixation of all
cells at the same time point to avoid variability between samples. In this way, all cells
were cultivated for the same period of time, being the dierences in viability and uptake
attributable to the eect of exosomes and not to the dierent times passed between the
seeding and the sample. For example, if fixation is to be performed at 1 PM of day 2:
 24 h dose will be added at 1 PM of day 1.
 4 h dose will be added at 9 AM of day 2.
 2 h dose will be added at 11 AM of day 2.
 1 h dose will be added at 12 PM of day 2.
 30 min dose will be added at 12:30 PM of day 2.
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3.14. Confocal microscopy
Fixation of samples from uptake studies was performed by adding the same amount of
formaldehyde 4% (Sigma-Aldrich) as culture media was in the wells, and incubating at
room temperature for 5 minutes. After that time, the content of the wells was carefully
removed with a pipette to avoid the aspiration of cells and 500 l of PBS are added.
For the assembly of microscope slides, 200 l of 4,6-diamidino-2-phenylindole 1:5000
(Sigma-Aldrich) were added per well and incubated 5 minutes at room temperature. Slip
glasses were lifted from the wells using pliers, washed in ultrapure water and placed
into covers using DAKO mounting media (Agilent, Palo Alto, CA). All quantifications
were performed in a blinded way. Image acquisition was carried out using the glycerol
ACS APO 20x NA0.60 immersion objective of a confocal fluorescence microscope (SPE,
Leica-Microsystems). To allow visualization of the near-infrared dye, excitation was car-
ried out at 647 nm.
Fiji was used for visualization and manipulation of the obtained images. Contrast
and brightness were adjusted for the merged images between channels. A small circular
region of interest (ROI) similar to the size of an U87 cell nucleus (13  14 pixels) was
defined and used to compare the intensity of sulfo-cyanine in the near-infrared channel at
the dierent time points of uptake. These intensities were normalized with respect to the
background [49].
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4. RESULTS
4.1. Isolation and purification of milk exosomes
Extensive amounts of proteins were satisfactorily removed with the developed protocol,
forming a layer of fat separated from the supernatant in the centrifuge tubes. The use of
curdling agent further improves the precipitation of fat, yielding exosomes with reduced
protein contamination when passed through the size-exclusion chromatography. The pro-
tein content of the fractions obtained from the PD-10 desalting columns was obtained in
order to optimize the recovery of exosomes and the elimination of the maximum amount
of contaminant proteins.
Fig. 7. Protein content of the PD-10 fractions. Exosomes isolated from 60 ml of commercial milk
were passed through the desalting column and eluted with PBS in 7 fractions. Proteins
were only noticeably present in fractions 1-4.
Exosomes start eluting in fraction 1, coeluting with small proteins, and continue in
fractions 2 and 3 with a high yield of exosomes. Fractions 4 and 5 contained only con-
taminant proteins, being discarded. The bulk of proteins elutes in fractions 2 and 3, being
their protein content 5 times higher than the content of fractions 1 and 4, as can be seen
in Fig. 7; this could be observed at naked eye since the turbidity of the fractions was
maximum for fractions 2 and 3, and almost unnoticeable in the rest. The fractions were
analysed with TEM (Fig. 8), not as a qualitative characterization, but to check whether
the increased presence of exosomes in the fractions correlates with the protein content
analysis.
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Fig. 8. Transmission electron microscopy comparing the eluted fractions from the PD-10
column. Images 1, 2, 4 and 5 were visualized using a magnification of 40,000 x; image 3
has a magnification of 60,000 x.
When selecting fractions 2 and 3, the amount of contaminant proteins is reduced and
the exosomes yield high purity, being easily identifiable. The result of analysing the pro-
tein content of the purified exosomes (when the appropriate fractions are selected) after
the optimized protocol is approximately of 199.3  8.4 g per 30 ml of commercial pas-
teurised milk (n = 4).
Additionally, the optimized protocol was used to obtain exosomes from dierent types
of milk in order to check the robustness of the method. Concretely, the protein content
per 30 ml of fresh unpasteurised milk was of 501.8  24.3 g (n=4). Higher amount of
obtained proteins (more than twice) and variability is observed for the unpasteurised milk
in comparison with the pasteurised milk.
4.2. Characterization of exosomes
The physicochemical properties of the obtained nanoparticles are examined and charac-
terized according to a variety of techniques to determine that the product obtained actually
corresponds to exosomes:
4.2.1. Transmission Electron Microscopy
Morphology and size were visually inspected, as well as the purity with respect to pro-
teins of the sample. The isolated vesicles are visually identified as exosomes (Fig. 9 panel
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a), having the expected cup-shape, size and intact morphology according to literature.
The shape and morphology of fresh unpasteurised milk-derived exosomes was also
characterized with TEM to visualize the dierences in protein contamination (Fig. 9
panel b). Observed abundance within the field of view is higher in unpasteurised milk,
together with a higher presence of protein contamination in comparison with commercial
milk. Additionally, dierences in size can be observed between the exosomes derived
from commercial pasteurised and from natural untreated milk, being the former smaller
than the latter.
(a)
(b)
Fig. 9. Transmission electron microscopic observation of morphology of isolated vesicles from
commercial pasteurised (a) and unpasteurised (b) goat’s milk with the optimized protocol.
Top left image was acquired with 80,000 x magnification, while top center and right
images have 200,000 x magnification. For bottom images, from left to right they were
acquired with 60,000 x, 80,000 x and 120,000 x magnification, respectively.
4.2.2. Dynamic Light Scattering
The hydrodynamic size distribution of the exosome populations was determined using
Dynamic Light Scattering (Fig. 10). For commercial pasteurised milk, the size distribu-
tion presents a narrow shape, obtaining a mean value of 135.32  9.12 nm (n = 3), while
for the untreated milk the shape is broader and the typical size of exosomes is 221.85 
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26.50 nm (n = 3). Additionally, the Z potential of pasteurised milk was measured, giving
a value of -12.57  0.58 mV.
Fig. 10. Hydrodynamic size distribution of commercial and natural exosomes using Zetasizer
Nano ZS.
4.3. Conjugation of milk exosomes with fluorophores for molecular
imaging
Exosomes derived from commercial milk were destroyed when conjugated with regular
Cyanine 7.5 NHS ester dissolved in DMSO; with the addition of the dye to the blank
exosomes, diculties in homogenisation were found, and the formation of an unexpected
solid precipitate was noticed (Fig. 11 left image). After the reaction, it was noticeable the
apparition of two dierentiated phases, one coloured and with a solid precipitate in the
bottom, and a transparent phase in the top. When purified with Exosome Spin Columns,
all the dye was retained in the top of the column, resulting in a low conjugation yield as
the typical green product was barely detectable (Fig. 11 centre and right images, right
samples respectively).
Fig. 11. Procedure: homogenisation of dyes (left images) with commercial milk-derived
exosomes, purification columns after the loading of the samples (centre) and final
product (right). In each image, the Sulfo-Cyanine is presented at the left, while the
samples conjugated with Cyanine is at the right.
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When conjugated with Sulfo-Cyanine 7.5 NHS ester dissolved in ultrapure water, exo-
somes were perfectly conjugated with the fluorescent probes being detectable by flow cy-
tometry and confocal microscopy; furthermore, the exosomes presented a greenish colour
at naked eye after the purification with the columns, sign of the incorporation of the dye
(left samples for each image in Fig. 11).
4.3.1. Characterization of conjugated exosomes
To ensure that the conjugation with Sulfo-Cyanine 7.5 NHS ester was not destructive or
causing noticeable alterations in the exosomal membrane or core size, TEM images and
flow cytometry analysis of pasteurised milk-derived exosomes were evaluated.
Fig. 12. Transmission electron microscopy of exosomes conjugated with Sulfo-Cyanine 7.5 NHS
ester. Images were visualized using 100,000 x and 150,000 x magnification, respectively.
Isolated exosomes of dierent sizes can be observed on Fig. 12, with their characteris-
tic cup-shape. The only observable dierence between blank and functionalized samples
is the intensity of the dark staining caused by negative staining of TEM. No major eects
were observed in shape or size of fluorescently labelled exosomes.
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When analysed by flow cytometry, similar patterns in terms of size and complexity
were obtained for blank and conjugated exosomes.
Fig. 13. Flow cytometry analysis of conjugation of Sulfo-Cyanine 7.5 NHS ester with the surface
of exosomes derived from pasteurised milk. Population and fluorescent event
distribution (left panel) and overlay of fluorescent events (right panel).
Between 30,000 and 40,000 events were measured for each of the samples. Both
control and functionalized exosomes showed similar population distribution (Fig. 13 left
panel). Blank (control) exosomes presented no fluorescence when compared with con-
jugated exosomes, which exhibited a 95.80% of fluorescent events with intensity high
enough to make the two populations distinguishable (right panel). Less than a 5% of
stained samples showed no fluorescence. Similar results were obtained for samples that
were frozen after their conjugation.
4.4. In vivo biodistribution in healthy animal
The examination of ex vivo imaging of organs (seen in Fig. 14) indicates that the biodis-
tribution in healthy animal of free Sulfo-Cyanine and conjugated exosomes is dierent.
Free dye is mostly accumulated (73%) in small and large intestines, kidneys (13%) and
liver (9%). With respect to the exosomes, they tend to gather in liver (60%), kidneys
(23%) and intestines (16%). Free Sulfo-Cyanine goes directly to the secretory pathway
while exosomes are gathered in liver. The right image presents an illumination artifact in
the bottom right corner.
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Fig. 14. Ex vivo imaging of accumulation of free dye (left) and conjugated exosomes (right) in
organs of healthy mice.
4.5. Cell culture
Culture of tumour-derived cells (B16F10, HeLa and U87) and primary hepatocytes was
successfully performed as explained in the Methodology. High confluences were obtained
and growth of cells in dierent culture plaques (24- or 96-wells, Flasks75, Petri dishes)
was possible without aecting the morphology or characteristics of the cells.
Fig. 15. Highly confluent cells of the dierent cell types cultivated. From left to right, top:
B16F10, HeLa; bottom: U87, hepatocytes.
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4.6. Validation of the conjugation technique
4.6.1. Isolation of cancer exosomes
Exosomes derived from cancer cells were isolated, conjugated and characterized. Three
dierent samples were analysed, one of each type of cancer cell exosomes (B16F10, HeLa
and U87). After the protein content analysis, non-homogeneous results in the protein con-
tent between the dierent samples were observed: for HeLa, 28  10 g were obtained
per 30 ml, while for U87, the isolation process yielded 83  3 g. In the case of B16F10,
the extraction yielded 43  9 g.
When analysing the size distribution, all the exosomes (Exo-Hela, Exo-U87 and Exo-
B16F10) presented consistent size within the range of exosomes (Fig. 16), with broader
distribution in comparison with commercial milk exosomes and similarities to the dis-
tribution of natural milk-derived exosomes. B16F10 and U87 exosome present similar
distributions, while HeLa has a wider distribution with the appearance of a small peak in
the range of 20 nm, indicating the presence of destroyed exosomes and small proteins.
The typical exosome size for the dierent cell lines are: 177  13 nm (n=2) for B16F10,
237.5  17.5 nm (n=2) for HeLa and 143  21 nm (n=2).
Fig. 16. Hydrodynamic size distributions of cancer cells-derived exosomes corresponding from
top to bottom to B16F10, HeLa and U87 exosomes.
U87 exosomes appear to be the smallest in size with the size distribution more shifted
to the left, and those derived from HeLa the largest ones as well as the most destroyed
ones; this is consistent with the typical exosome size.
4.6.2. Conjugation of cancer exosomes with fluorophores
For the flow cytometry, a gate separating two dierent populations, one more concentrated
containing smaller events and other with a broader size distribution of bigger events were
defined. It was observed that all samples, both labelled and blank, fulfilled the gate for
population distribution except the control blank exosomes obtained from HeLa (Fig. 17
top panel), which presented an increased population of events with smaller size than the
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traditional diameter of exosomes. Furthermore, fewer events were detected in the labelled
exosomes in comparison with the blank samples.
jfjfjfjfjfjfjfjfjfjfjfjfjfjfjf
jfjfjfjfjfjfjfjfjfjfjfjfjfjfjf
Fig. 17. Flow cytometry analysis of blank and fluorescently labelled exosomes in the near
infrared spectrum. Population distribution and the designed gates (left panels). Overlay
of fluorescent events from control and conjugated exosomes (right panel). From top to
bottom, rows correspond to B16F10, HeLa and U87 exosomes.
When analysing the dierences in fluorescence (Fig. 17 right panel), blank exosomes
present a minimum fluorescent signal, while exosomes conjugated with near-infrared dye
show intense fluorescence. Exosomes from U87 and B16F10 present a high percentage
of fluorescent events, indicating than more than the 99% of the exosomes are marked;
for Hela-derived exosomes, this percentage is reduced to 83%, showing some small-sized
events that did not get stained.
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Size and morphology of exosomes were examined in order to determine the belong-
ing of the obtained vesicles to the exosome category. As goat’s milk exosomes and others
reported in literature, tumoral exosomes presented rounded cup-shape with negative stain-
ing, of congruent sizes for both stained and unlabelled samples of all tumoral cell lines.
(a) (b)
Fig. 18. Comparison of TEM images of the treatment of tumoral cells with blank (a: control, left
panel) and conjugated (b: right panel) exosomes. From top to bottom, the inspected cells
are B16F10, HeLa and U87.
Images from unlabelled exosomes can be seen in the left panel and those of func-
tionalized exosomes in the right panel; for both, rows correspond from top to bottom
to B16F10, HeLa and U87 cells respectively. No observable dierences are appreciated
between left and right panels. Additionally, HeLa exosomes appeared destroyed, being
congruent with the results obtained from flow cytometry analysis, in which unstained
peaks were observable as well as a reduced number of events once labelled.
4.7. In vitro toxicity assessment
To investigate the short-term toxicity of exosomes in cancer and hepatic cells, these were
treated with blank exosomes derived from pasteurised milk (to avoid any eect of the
NIR dye to the absorbance measurement) at various concentrations (0-20 g/ml) and the
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viability was tested with MTT assay at 24 and 48 hours from the dose addition.
Concentrations of 0 (control), 0.05, 0.5, 5 and 20 g/ml doses were added to hepato-
cytes cultured in vitro for at least 24 hours from the liver extraction (according to section
3.9 from Methodology). Absorbance was measured at 595 nm and results were normal-
ized with respect to the null dose.
At 24 hours it is observed that absorbance (and therefore the viability of cells) is
slightly below the zero value (Fig. 19 left panel). The increase in the exosome dose does
not appear to have any eect on the viability of hepatocytes. A small increase in the
absorbance can be observed for the higher dose. At 48 hours similar results are obtained,
with the viability maintained constant at the zero value for all concentrations (Fig. 19
right panel).
Fig. 19. Hepatic cells were treated in vitro with dierential doses (0-20 g/ml) to test short-term
toxicity (at 24 and 48 hours) of exosomes using MTT assay.
Visual inspection of cells using light contrast microscope provided no further infor-
mation, as the number of living cells was high and no cell death was obvious at naked
eye. No significant toxicity nor observable eects in the number and morphology of cells
were found.
Fig. 20. Visual inspection of hepatocytes at 48 hours after the addition of 0 g/ml (control, left
image) and 5 g/ml (right image) of blank exosomes.
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An additional MTT assay was performed to analyse the toxicity of exosomes in cancer
cells (mouse melanoma B16F10, human adenocarcinoma HeLa and human glioblastoma
U87). Doses between 0 and 20 g/ml were used and the absorbance caused by cellular
activity was measured; additionally, the absorbance of the dierent doses of exosomes in
culture media was analysed.
Fig. 21. Analysis of viability of cancer cells treated in vitro with dierential doses (0-20 g/ml)
to test short-term toxicity (at 24 and 48 hours for left and right panels respectively) of
exosomes using MTT assay. From top to bottom, rows correspond to B16F10, HeLa and
U87 exosomes.
At 24 hours (Fig. 21 left panel), for B16F10 cells, absorbance was close to the zero
value for lower doses. For the highest ones it was slightly over zero. In the case of HeLa,
same results were obtained for 0.05 and 0.5 g/ml doses, while the increase in the highest
ones is more noticeable. With respect to U87, only the lowest dose is close to zero, while
the other three (0.5, 5 and 20 g/ml) show important increases in absorbance.
At 48 hours (Fig. 21 right panel), less homogeneous values are obtained, in general
showing an increasing absorbance when the dose is incremented. The exceptions are the
5 g/ml doses of HeLa (being its absorbance lower than the 0.5 g/ml dose) and U87
(showing an unexpected higher value than the highest dose).
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Additionally, visual inspection of cells was performed at 48 hours before the MTT as-
say (Fig. 22), for B16F10 showing how cells of wells where high doses had been applied
(5 and 20 g/ml) were totally destroyed, while for 0.5 and 0.05 g/ml cells appeared to
have strange morphologies and presented aggregation. In the case of HeLa, cells of higher
doses were barely visible, rounded or destroyed, while at 0.5 g/ml and 0.05 g/ml they
presented aggregation and abnormal morphology. For U87, cells from 20 g/ml wells
were destroyed; 5 g/ml and 0.5 g/ml presented rounded morphology and aggregation,
and 0.05 g/ml appeared to be unaected. Cells of wells with no dose presented normal
morphology and growth, covering the whole bottom of the well (similar to those in Fig.
15).
Fig. 22. Visual inspection of cancer cells at 48 hours after the addition of exosomes.
To analyse whether this eect may be caused by interference of exosomes with the
MTT assay, the absorbance of exosomes in medium with collagen (with no cells seeded)
was also measured (Fig. 23). At 24 hours, doses of 5 g/ml and 20 g/ml rendered high
unforeseen absorbances, in comparison with the lowest doses that did not present any
absorbance (as expected). For measurements taken at 48 hours, absorbance was detectable
for all concentrations.
Fig. 23. Measurement of the absorbances of exosomes seeded in medium with collagen for
dierent dose concentration (0-20 g/ml) and periods of time (24 and 48 hours).
Moreover, when the wells containing only exosomes onmediumwith collagen-covered
bottom were observed through the microscope, the bottom of the well appeared to be cov-
33
ered by a rough network of higher density for the higher doses. Wells containing only
collagen and medium did not present this “carpet”, seen in Fig. 24.
Fig. 24. Visual inspection of wells containing exosomes in medium with collagen at 48 hours
after the addition of blank exosomes.
4.8. In vitro uptake studies
To investigate the in vitro cell uptake of pasteurised milk-derived exosomes, mouse melanoma
B16F10 cells, human adenocarcinoma HeLa cells and human glioblastoma U87 cells
were treated with Sulfo-Cyanine7.5-conjugated exosomes at various concentrations (0.5
and 5 g/ml) and durations (0.5-24 hours).
The cellular internalization of exosomes was examined using confocal microscopy;
no significant uptake was detected at any time for B16F10 neither HeLa cancer cells (top
panel of Fig. 25). On the contrary, a time-dependent increase was observed for U87 cells
(bottom panel of Fig. 25). Similarly, the higher concentration presented higher uptake
during time, being the uptake for the lower dose almost unnoticeable for all cell lines.
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Fig. 25. Uptake of milk exosomes by cancer cells. (A) Confocal images of uptake experienced by
the dierent cells at dierent time points for 5 g/ml. (B) Quantification of fluorescent
intensity, showing a time-dependency for U87 cells with dose 5 g/ml.
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Dierent areas of the cells were evaluated, revealing that exosomes tend to localize
non-uniformly inside the cells, as the perinuclear region presented higher intensities than
the distal regions of the membrane and the nucleus (bottom panel of Fig 25). The localiza-
tion of exosomes in the perinuclear area is quantified, being congruent with the tendency
observed in the confocal images. The time dependency with respect to the intensity ob-
served for U87 cells at higher dose does not present any linearity, but a general exponential
behaviour in which increased intensity in the near infrared channel is observable.
36
5. DISCUSSION
The focus of this Bachelor Thesis was the evaluation of goat’s milk-derived exosomes
as a new theragnostic platform in oncology, due to the particular characteristics of lipidic
membranes of exosomes that allow their use as substitute of liposomes. To do so, the
viability of goat’s milk as source of exosomes and the hypothesis stated (such as the lack
of toxicity or tumorgenicity) had to be confirmed.
Due to the enormous variety of exosomes present in dierent biological samples, sev-
eral extraction methods can be found in literature to maximize the yield and purity and
reduce the destruction of exosomes depending on the complexity of the method and the
biological sample from which exosomes are obtained. Some of these methods are based
on physicochemical properties such as dierential centrifugation, filtration or density gra-
dients, while others exploit biochemical reactions. The presented protocol combines both
physico- and biochemical processes, using dierential ultracentrifugation, size-exclusion
chromatography and curdling agent to optimize the purity of the obtained exosomes. Us-
ing this optimized protocol and selecting the appropriate milk, the protein content is re-
duced to its minimum and the yield of pure exosomes is maximized.
Additionally, exosomes from goat’s milk, either commercial skimmed pasteurised or
direct from the goat, not treated, were characterized to evaluate which one is more suit-
able for research purposes. Being both visually identified as exosomes with Transmis-
sion Electron Microscopy as exosomes, showing the characteristic cup-shape and being
in the size range and morphology typical of exosomes according to literature, it can be
concluded that the aforementioned protocol allows the isolation of purified and intact ex-
osomes in high yields.
Depending on their origin, milk exosomes show distinct characteristics, mainly dif-
ferences in the hydrodynamic size distribution and the protein content. The amount of
protein in micro-grams of fresh unpasteurised milk doubles the protein concentration
obtained from commercial skimmed pasteurised milk, indicating that the pasteurisation,
skim and treatments performed in the dairy industry reduces notably the exosome content
of the samples. Additionally, exosomes of dierent sizes are identifiable in TEM images
of untreated milk, which agrees with the broader hydrodynamic size distribution of exo-
somes obtained from these samples, which implies a higher heterogeneity in size. This
is caused by vesicles gathering in accumulation of exosomes embedded in proteins, due
to the increased protein content of these samples. This aggregation of higher number of
exosomes diverse in size is not appreciable for pasteurised milk-derived exosomes. Thus,
DLS results are consistent with the information extracted from the TEM images, which
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showed the dierences in size between the exosomes derived from the distinct milks and
indicates that the broader size distribution for unpasteurised milk is caused by aggrega-
tions of exosomes. The exosome size was therefore confirmed to be within the range of
50-200 nm stated in literature.
The comparison between commercial and fresh natural milk was carried out in or-
der to determine the optimal source for the stated purposes; it was observed that skim
pasteurisation at 72oC did not cause destruction of the exosomes, but rather eliminated
undesired proteins from the samples. Although the protein content and the number of
exosomes appears to be significantly lower in the commercial milk, its availability at reg-
ular stores, its size homogeneity and lower amount of contaminant proteins makes it more
suitable for scientific research.
Since one of the intentions of this Thesis is to use exosomes as natural liposomes in
oncology using optic imaging in vivo, exosomes needed to be functionalized with fluo-
rophores, as they don’t naturally present fluorescence. Probes in the near-infrared range
were used to avoid interference caused by the autofluorescence of tissues and to prevent
the loss of absorption by tissues.
There already exist commercial kits that functionalize exosomes based on their hy-
drophobicity, coating the vesicle with a thin-layer of dye maintained with weak bonds
that are easily degraded, not being resistant to the dierent processes to which exosomes
are subjected when used as theragnostic platform in vivo. Due to this lack, a chemical
tool for robust conjugation of exosomes was developed and optimized by exploiting the
covalent bonds that can be formed between the lipidic membrane of exosomes and the
selected NHS ester dyes. This strong covalent bond stablished between the fluorophore
and the exosome will avoid possible false positives caused by the detachment of the dye
from the vesicle and allowing the tracking of the exosome over time and dierent con-
ditions. As far as I know, there is no bibliography regarding the covalent conjugation of
exosomes with fluorophores in vivo, being this work the firs approach developed in the
covalent conjugation of exosomes.
Exosomes were conjugated with Cyanine and Sulfo-Cyanine 7.5 NHS ester. The dif-
ferences between them consist on the sulfo groups present in the Sulfo-Cyanine, which
makes the dye hydrosoluble instead of soluble in organic solvents as Dimethyl Sulfoxide,
which has proved to destroy the exosomes.
Characterization of functionalized exosomes showed a high yield in the conjugation,
indicating that exosomes can be robustly conjugated with NHS ester fluorophores. Addi-
tionally, the chemistry does not alter the membrane nor destroy the exosome, as TEM and
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flow cytometry analysis confirmed. No significant dierences in shape, size, complexity,
general aspect or function between stained and blank exosomes were found; the only ob-
servable dierence between blank and dyed samples is the intensity of the dark staining
caused by negative staining of TEM. This could be caused by a slight change in the Zeta
potential, which changed from -12.57  0.58 mV to -11.93  0.047 mV.
From the characterization, it can be deduced that the exosomes are resistant enough so
that they are not degraded by the chemistry of conjugation and the purification with exo
spin columns. Additionally, the fluorescent signal, situated in the near infrared spectrum,
is strong enough to allow its detection not only in vitro experiments but also in vivo in
healthy animals. From this experiment, which was carried out without my participation,
it was demonstrated the dierent pathways undergone by free dye and labelled exosomes.
This consistently demonstrates that the labelling does not aect the biodistribution of ex-
osomes, as they notably accumulate in liver (60% of uptake in comparison with 23% of
kidneys) as reported on literature [15].
Furthermore, the verification of robustness of the conjugation method for dierent
and less resistant exosomes was accomplished. For this, the isolation, characterization
and labelling of tumoral exosomes was carried out following similar procedures as those
stated in the Methodology section except for the isolation, which was performed using a
simplified dierential centrifugation protocol with no purification steps.
The advantages of performing this validation in cancer exosomes is not only the afore-
mentioned, but also a comprehensive understand about the physicochemical characteris-
tics of tumoral exosomes may help researchers to discern pathways or related mechanisms
of the metastatic processes, since exosomes have proved to be involved in pro-oncogenic
and metastatic processes, altering the tumour microenvironment and exchanging informa-
tion for tissue preparation prior colonization. Additionally, the presence of these extracel-
lular vesicles in body fluids have been used as biomarkers of the disease; the possibility
of tracking the position of tumoral exosomes within the body in real time using molecular
imaging opens the door to diagnosis of metastasis before its actual appearance, and would
improve our understanding on tumour development.
The non-homogeneous results obtained regarding the protein content between the dif-
ferent samples were possibly due to the number of cellular passages that the cells had
been subjected and the number of days of culture before the medium was retired. More
extractions would be required to establish if the variations between the protein content
in micrograms was due to the aforementioned dierences in cellular stage, or caused by
intrinsic dierences in the exosomal production between the distinct cell types.
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The dierences between the fulfilment of the gates regarding the population distribu-
tion for blank and conjugated exosomes lead to the conclusion that the labelling or the
exo spin columns are aecting the exosome or, at least, reducing the impurities. These
dierences in size between the types of exosomes are also observable in TEM images,
due to the dierences in the species of origin and cell type. Still, their morphologies and
sizes are ranging between those described in literature, being possible to arm that the
reported nanovesicles are indeed exosomes derived from tumoral cells.
More numerous signs of destruction were found in the characterization of these ex-
osomes than those observed for milk-derived exosomes, confirming the hypothesis that
cancer exosomes are less resistant than milk ones, since they are more destroyed with
a less aggressive isolation process. Despite their fragility, blank and labelled exosomes
were analysed by TEM and flow cytometry; with the exception of HeLa exosomes, they
were satisfactorily isolated and conjugated, showing the characteristic cup-shape and size
range and allowing their confirmation as exosomes. Additionally, the overlay of flow cy-
tometry analysis indicates that exosomes are labelled in more than a 99% of cases for
B16F10 and U87, while only an 85% of conjugation was obtained for HeLa. This is con-
sistent with the fact that HeLa exosomes were destroyed, as seen in the TEM images and
in the hydrodynamic size distribution. This may indicate that only exosomes are being
conjugated, but in any case, it is a sign of the robustness of the conjugation technique,
which allows the functionalization of even delicate exosomes.
The capability of tumoral exosomes to be conjugated with the proposed optical dye
with satisfactory results is demonstrated; among the dierent studied types, those derived
from U87 cells appear to be the ones with better eciency. The implications of this con-
jugation are mainly its use in molecular imaging, which could provide important insights
into the biodistribution of tumoral exosomes and supply valuable information about the
future behaviour of the primary tumour and possible metastasis.
As exosomes are proposed as natural, non-toxic liposomes, their toxicity was tested
in both host cells (hepatocytes directly obtained from euthanized animals) and dierent
tumour models. Between the diverse assays to determine toxicity and viability, a tetra-
zolium assay (concretely MTT) was selected due to its reduced price, its suitability for
high throughput screening and its non-radioactivity. This technique is based on the re-
duction of MTT substrate into purple-coloured formazan by cells with active metabolism
being the colour a marker of viability of the cells.
Hepatocytes showed nearly unaltered absorbances, and thus, unaected proliferation
and viability with respect to the control, indicating that exosomes do not harm host cells
where the uptake is greater in healthy animal. This was checked by visual inspection of
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the cells at 48 hours; since no observable dierences were remarkable, it can be assumed
that the above hypothesis is true. In the case of cancer cells, absorbance values were
dierent from cero, especially for 48 hours; this may indicate that exosomes benefit pro-
liferation of cancer cells, but visualization with light phase microscope shows destruction
or, at least, substantial abnormalities in morphology, number and distribution, signifying
that exosomes present an anti-oncogenic behaviour rather than causing their prolifera-
tion. This destructive eect was not observed in the control wells, where no dose had
been added, indicating that this disaggregation of the tumour environment was caused by
the goat’s milk-derived exosomes.
The hypothesis that explains this discrepancy between the MTT assay results (which
suggest that the viability and proliferation of cancer cells is incremented by the addition
of exosomes) and the information retrieved by visual inspection (which support that exo-
somes cause some grade of disruption of normal behaviour of cancer cells) suggest that
exosomes have some sort of pseudo-cellular behaviour, presenting metabolic activity and
causing reduction of the MTT substrate. To check this, a separate study only with dier-
ent concentrations of exosomes was carried out; it was observed that increased absorbance
values were measured, coinciding exactly with the high absorbance measured for cancer
cells. This consistency indicates that the absorbance measured when the cells were de-
stroyed was indeed caused by the exosomes, which are deposited in the collagen-covered
bottom. The collagen itself cannot be the cause of the interference since controls did not
presented any incremented absorbance.
In order to further analyse these findings, additional experiments were designed to per-
form MTT assay on half of the cells and confocal microscopy analysis of the other half at
both 24 and 48 hours, in an attempt to identify the causes of such dierentiated eects on
healthy and aberrant cells. These would have probably been the next steps in the research.
The uptake ability of tumour-derived cells was examined in order to determine the
possibility of success of accumulation of the fluorescent probe in tumours in vivo exper-
iments. Although the Enhanced Permeability and Retention eect allows the hypothetic
gathering of nanosized vesicles in the tumour, this accumulation would be strongly in-
creased by the tendency of the tumour itself to uptake nanoparticles. Exosomes have
been demonstrated in literature to be able to be internalized by cells [36], being this eect
extremely desirable to use the exosomes as drug carriers for oncologic therapy. It was ob-
served that the dierent cell lines respond dierently to exosomes, being the glioblastoma
U87 cells the only ones presenting noticeable uptake denoted by a detectable increased
intensity in the near infrared channel.
Going into details, for the evaluation in tumour model, the uptake study was carried
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out in order to select the most appropriate cancer cell line to be translated into an in vivo
model. The behaviour of exosomes was evaluated in the same cancer cell lunes that were
used in the toxicity assessment. Since the platform was designed as theragnostic platform,
the distribution at cellular level results of high relevance; for this, dierent areas were
evaluated, leading to the conclusion that uptake of exosomes by cells mainly takes place
at the perinuclear area of the cytoplasm rather than inside the nucleus; this is consistent
with literature [15]. While several problems were encountered with the autofluorescence
of cancer cells, even in the near infrared spectrum, dierences in the intensity (and there-
fore in the uptake of NIR fluorescent by the distinct cell types) were observed at several
time points and concentrations. In general, it was observed a dependency between the
concentration of the dose and the intensity measured, such as that the higher the dose, the
more incremented the intensity.
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6. FRAMEWORKS
6.1. Socioeconomic framework
Malignant tumours, together with diseases of the circulatory system, are the two leading
causes of death in the world. Specifically, in Spain during 2016, they represented the
26,8% and 29,7% respectively, according to the ‘Reporte Anual del Sistema Nacional de
Salud 2016’ [53], developed annually by the Spanish Government. The mortality caused
by cancer was of 112,939 deceases during the aforementioned year; among the dierent
types of cancer, colon, prostate, lung and breast cancer are the most common.
In an attempt to identify the economic impact of this disease, several terms must be
defined [54] [55]:
 Direct costs: they represent the value of the resources from the National System of
Health required to prevent, detect and treat a health problem. They are constituted
by the primary attention, hospital and anti-cancer drugs costs.
 Indirect costs: referred to the value lost by the lack of productivity occasioned by
the disability or death of the patient. In this section, costs derived of the informal
care – that is, the attention received by a person with limited autonomy to perform
their daily tasks – is also included.
 Intangible costs: related to the non-monetary consequences of the disease, like the
pain.
The estimation methods of these costs are mainly two, which can yield very dieren-
tiated results:
 Human-capital: it considers the patient’s perspective, counting any hour not worked
as a lost one.
 Friction-cost: it takes the employer’s perspective as it contemplates as lost hours
only those that have not been worked, until another employee substitutes the pa-
tient and carries out their work.
For the analysis of the economic impact in this thesis, the human-capital method will
be used; the intangible costs were not included. Using the selected human-capital method,
the total costs of malignant tumours during 2015 in Spain were 12,216 million of euros,
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being a 60% of them derived from indirect costs. This figure represents the 11.3% of the
Gross Domestic Product of the country during that year, and accounted for a 17% of the
total sanitary costs (calculations performed with data obtained from the AnnualSpanish
National Health Report [53].
As it can be seen in the aforementioned report, the economic impact of cancer in Spain
each year is enormous. It is required the development of a system that would allow the
early detection of primary and metastatic tumours; this premature diagnosis increments
the survival rate of patients and thus, reduces the costs associated with loss of productiv-
ity. Moreover, the improvement in diagnosis and therapy techniques against cancer will
result in increased life expectancy and wealth for the patients, especially taking into ac-
count that the proposed theragnostic system is non-invasive and non-radioactive, which
improves patient’s quality of life [56]. Thus, the social impact of the exosomes used as
nanocarriers produces a noticeable social impact that must be considered in light of the
numbers provided.
An additional impact that may not result noteworthy at first sight, but in view of fur-
ther exploitation plans acquires importance, is the ethical impact of both the investigation
and the profiteering intention. For the research, goat’s milk was used to obtain the exo-
somes, instead of human maternal milk as other papers use during their research [4]. Not
using human products as basic materials during the development of this work supposes
the inexistence of further ethical issues apart from those derived from the use of animal
models and human tumour cells [57] (as well as the caprine milk and other animal prod-
ucts typically used in research), which will be itemised in next section.
This lack of human origin products facilitates the exploitation plan, which consists
mainly on the commercialization of conjugated exosomes in optimized doses for direct
injection at the hospital. The resulting product would be hospital-oriented, not for in-
dividual use at home; therefore, it would be supplied directly to the health service in a
similar way that vaccines or other treatments do.
Being the exosomes an extremely versatile chemotherapeutic platform with a wide
range of applications [50], dierent methods of utilization can be developed with these
fluorescently labelled nanoparticles. Some of these applications could be the diagnostic
of inflammatory processes or bacterial infections, or treatments based on the alteration
of the exosomal cargo (as several papers have already suggested [15] [35]) for cancer
therapy.
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6.2. Regulatory framework
As biological experiments were necessary to carry out this project, several regulation sets
concerning the risk prevention during laboratory activities are considered, according to
the national Spanish laws:
 Real Decree 664/1997: related with the protection of workers against risks related
with the exposure to biological reagents.
 Real Decree 83/1999: regulation of the production and management of biosanitary
and cytotoxic residues in the autonomous region of Madrid.
 Real Decree 53/2013: by which the basic regulations applicable for the protection
of animals used in experimentation and other scientific purposes, including teach-
ing, are established.
 Real Decree 223/2004: regulation of the clinical trials with medicines.
 Law 28/2009: regarding the guarantees and the rational use of medicines and other
sanitary products.
 Real Decree 577/2013: which regulates the pharmacovigilance of medicines for
human use.
In order to apply for authorisation, it is essential to have the favorable reports of the ethics
Committee on Animal experimentation at the centre and an autonomous community-
enabled body for project evaluation. In addition, the sta who will participate in the
experiments must be previously trained according to the RD 53/2013 and the Order ECC
566/2015.”
6.3. Budget
The following section shows the budget associated with the research developed during
the last months at the ‘Unidad de Medicina y Cirugía Experimental’ from the Gregorio
Marañón Hospital. As other biomedical investigations, several expensive materials were
required; these costs are separated according to the part of the experimental procedure
they correspond, but only the final costs per section are showed; an itemisation of the
costs per section can be found in the Appendix:
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Section Total costs (e)
Extraction 173.1
Purification 1,062.10
Characterization 1,081.00
Conjugation 988.90
Cell culture 1,412.92
Toxicity studies 189.16
Uptake studies 888.15
General laboratory supplies 2,272.60
Licenses and extra costs 6,786.00
Total 14,853.93
Table 2. Budget of the dierent sections of the research and total costs
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7. CONCLUSIONS AND FUTURE PERSPECTIVES
7.1. Conclusion
Once the dierent methodologies, hypothesis and experiments have been itemised and
evaluated throughout this dissertation, dierent conclusions and main ideas can be ex-
tracted, among them, the most important ones are the confirmation that goat’s milk ex-
osomes are satisfactorily isolated, purified and characterized for the first time with the
proposed protocol.
Although the hypothesis of the ideality of exosomes as substitute of liposomes has not
been fully developed, it can be armed that exosomes constitute a promising platform as
natural replacement of artificial liposomes, especially in the area of oncology.
Additionally, the designed novel conjugation method of exosomes with fluorescent
molecules is robust and allows the labelling of dierent types of exosomes with fluo-
rophores for their use in optical imaging with a high yield (higher than 95%) and causing
no modification of the properties of exosomes. This validates their use in molecular imag-
ing as part of the optical techniques.
In vitro toxicity studies show that exosomes do not present toxicity against host cells
(hepatocytes), but appear to destroy tumour cells. Furthermore, viability assay based on
metabolic activity shows that exosomes present pseudo-cellular behaviour. These proper-
ties suppose that their use in oncology could be of great importance.
It has been confirmed that milk-derived exosomes present dierent behaviour in pres-
ence of distinct cancer cell lines, with the highest uptake in the is U87 cell line (glioblas-
toma). Moreover, exosomes extracted from dierent cancer cell lines show dierentiated
behaviour and physico-chemical properties depending on their origin. It can be then con-
cluded that exosomes present dierentiated behaviour in distinct circumstances, as well
as acting dierently in similar situations due to their variated origin.
In general, it can be armed that the main objective of the Thesis, that is, the evalua-
tion of exosomes as new theragnostic platform in oncology, as well as the subobjectives
stated to carry out this evaluation, have been satisfactorily performed, yielding robust and
consistent results.
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7.2. Future perspectives
Although this primary evaluation yielded solid conclusions, further research needs to be
done in order to ensure a safe translation to the clinic and the oncologic area. The most
important ones, in my consideration, are the evaluation of the pseudo-cellular behaviour
of exosomes, which apart from noteworthy, could cause interference with the therapy
treatments, and the analysis of the suggested anti-oncogenesis properties of exosomes.
The following step on this Thesis would have been, apart from the aforementioned,
the translation to an subcutaneous in vivo model in small animal of glioblastoma in order
to analyse the ability of exosomes to be recruited in tumours. Additionally, related with
the use of exosomes as natural liposomes for therapy, the alteration of exosome active
cargo for drug therapy has necessarily to be addressed.
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APPENDIX
Item Quantity Unit cost |e| Total cost |e|
Goat’s milk 2 bottles 3.56 7.12
Ultracentrifuge tubes 1 pack of 6 165.98 165.98
Table 1. Budget for exosome extraction
Item Quantity Unit cost |e| Total cost |e|
Curdling agent 1 bottle 5.50 5.50
PD-10 desalting columns 2 boxes of 30 units 286.80 573.60
0.44 m filter 1 box 50 units 161.00 161.00
Exosome spin columns 2 boxes of 30 units 161.00 322.00
Table 2. Budget for purification
Item Quantity Unit cost |e| Total cost |e|
Bovine Serum Albumin 1 bottle 100 g 463.00 463.00
Coomassie Blue 2 bottles 114.00 228.00
Cytometer session 5 hours 6.00 30.00
TEM session 10 hours 36.00 360.00
Table 3. Budget for characterization
Item Quantity Unit cost |e| Total cost |e|
Cyanine 7.5 NHS ester 2 bottles of 5 mg 210.00 420.00
Sulfo-cyanine 7.5 NHS
ester
2 bottles of 5 mg 275.00 550.00
Sodium Bicarbonate
(NaHCO3)
1 bottle 500 g 18.90 18.90
Table 4. Budget for conjugation
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Item Quantity Unit cost |e| Total cost |e|
Rapid flow filter units 1 box of 12 units 119.00 119.00
Culture plaques 24 wells 1 box of 50 units 171.10 171.10
Culture plaques 96 wells 1 box of 50 units 533.70 533.70
Disposable serological
pipettes 10 ml
2 boxes of 30 units 161.00 322.00
Disposable serological
pipettes 10 ml
2 boxes of 200 units 65.10 130.20
RPMI medium 4 bottles 16.03 64.12
DMEM medium 3 bottles 9.00 27.00
PBS for cell culture 3 bottles 18.90 56.70
Trypsin 10x 1 bottle 100 ml 25.10 25.10
FBS 1 bottle 100 ml 15.95 15.95
Glutamine 1 bottle 100 ml 15.85 15.85
DMSO 2 bottles 66.50 133.00
HeLa cells 1 vial
Ceded by Culture
Unit from G.M.
Hospital
-
U87 cells 2 vial
Ceded by Culture
Unit from G.M.
Hospital
-
Hepatocytes 4 vial
Ceded by Culture
Unit from G.M.
Hospital
-
Table 5. Budget for cell culture
Item Quantity Unit cost |e| Total cost |e|
Thiazolyl Blue
Tetrazolium Bromide
(MTT)
1 bottle of 100 mg 16.16 16.16
0.22 m filter 1 box of 50 units 173.00 173.00
Table 6. Budget for toxicity studies
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Item Quantity Unit cost |e| Total cost |e|
Confocal microscope
session
8 hours 7.00 42.00
DAPI 1 bottle of 1 mg 9.90 9.90
Microscope slide 1 box of 100 units 31.60 31.60
Cover slip glass 1 bottle of 15 ml 63.60 63.60
DAKO Fluorescent
Mounting media
1 bottle of 15 ml 92.00 92.00
Collagen type I from rat
tail
1 bottle of 25 ml 210.00 210.00
Naubauer chamber 1 unit 200.00 200.20
Haemocytometer cover
glasses
1 box 100 units 184.30 184.30
Trypan Blue 1 bottle 20 ml 10.30 10.30
Formaldehyde 1 bottle 250 ml 44.25 44.25
Table 7. Budget for the uptake studies
Item Quantity Unit cost |e| Total cost |e|
Variable Volume Pipettors
Set of 3 spanning
from 0.5 to 1000 l
312.00 312.00
Pipette tips 15 boxes of 200 units 62.16 932.40
Falcon 50 ml 2 boxes 500 units 168.40 336.80
Falcon 15 ml 2 boxes 500 units 163.60 327.20
Parafilm 2 units 38.00 76.00
PBS tablets 1 box of 100 units 185.00 185.00
Eppendorf 2 boxes of 1000 units 45.60 91.20
pH test strips 1 box 12.00 12.00
Table 8. Budget for general laboratory supplies
Item Quantity Unit cost |e| Total cost |e|
Matlab 2017.b 1 license 2000.00 2000.00
Computer with basic
oce software
1 device
540.00 540.00
Working hours 400 hours 10.00 4000.00
Prism 5 1 license 246.00 246.00
Image J 1 license Free software -
Microscope Imaging
software
1 license Free software -
Table 9. Budget for licenses and extra costs
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